Top-Rated StocksTop-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $54.75 -0.49 (-0.89%) Closing price 02/4/2025 04:00 PM EasternExtended Trading$55.00 +0.26 (+0.47%) As of 02/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Exact Sciences Stock (NASDAQ:EXAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exact Sciences alerts:Sign Up Key Stats Today's Range$54.23▼$56.2550-Day Range$50.44▼$64.1452-Week Range$40.62▼$79.62Volume1.41 million shsAverage Volume2.32 million shsMarket Capitalization$10.13 billionP/E RatioN/ADividend YieldN/APrice Target$72.76Consensus RatingModerate Buy Company OverviewExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More… Exact Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks96th Percentile Overall ScoreEXAS MarketRank™: Exact Sciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 44th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 18 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($1.10) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -46.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -46.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.56% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Exact Sciences has recently decreased by 3.74%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.83 Percentage of Shares Shorted5.56% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Exact Sciences has recently decreased by 3.74%, indicating that investor sentiment is improving. News and Social Media3.5 / 5News Sentiment1.31 News SentimentExact Sciences has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Exact Sciences this week, compared to 9 articles on an average week.Search Interest17 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat Follows12 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,001,325.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesExact Sciences Schedules Fourth Quarter 2024 Earnings CallFebruary 3 at 7:01 AM | businesswire.comExact Sciences: Liquid Biopsy Threat Is SolidifyingJanuary 27, 2025 | seekingalpha.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?February 5, 2025 | Behind the Markets (Ad)Barclays Begins Coverage on Exact Sciences (NASDAQ:EXAS)January 26, 2025 | americanbankingnews.comExact Sciences initiated with an Overweight at BarclaysJanuary 24, 2025 | markets.businessinsider.comBarclays Initiates Coverage of Exact Sciences (EXAS) with Overweight RecommendationJanuary 24, 2025 | msn.comBarclays sets Exact Sciences stock price target at $70 with Overweight ratingJanuary 23, 2025 | msn.comExact Sciences validates Oncodetect ability to detect molecular residual DiseaseJanuary 22, 2025 | markets.businessinsider.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $56.19 at the beginning of the year. Since then, EXAS shares have decreased by 2.6% and is now trading at $54.75. View the best growth stocks for 2025 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Tuesday, November, 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The firm's revenue was up 12.8% compared to the same quarter last year. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. Who are Exact Sciences' major shareholders? Top institutional investors of Exact Sciences include Baillie Gifford & Co. (0.55%), Sumitomo Mitsui Trust Group Inc. (0.51%), C WorldWide Group Holding A S (0.45%) and Principal Financial Group Inc. (0.44%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/05/2024Today2/04/2025Next Earnings (Estimated)2/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$72.76 High Stock Price Target$90.00 Low Stock Price Target$60.00 Potential Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-7.95% Pretax Margin-7.82% Return on Equity-6.17% Return on Assets-2.98% Debt Debt-to-Equity Ratio0.72 Current Ratio2.12 Quick Ratio1.93 Sales & Book Value Annual Sales$2.50 billion Price / Sales4.05 Cash Flow$0.02 per share Price / Cash Flow3,291.11 Book Value$17.39 per share Price / Book3.15Miscellaneous Outstanding Shares185,080,000Free Float182,559,000Market Cap$10.13 billion OptionableOptionable Beta1.24 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:EXAS) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.